Black Diamond Therapeutics appoints Shannon Campbell and Prakash Raman to board; Dixon and Mayweg resign

Black Diamond Therapeutics, Inc.

Wendy Dixon and Alex Mayweg resigned from board effective April 10, 2024; no disagreement cited.
Shannon Campbell (EVP/Chief Commercial Officer at Merus) appointed Class III director, will serve on Compensation Committee.
Prakash Raman (CEO of stealth biopharma) appointed Class I director, will serve on Audit and Nominating/Governance Committees.
New directors are independent under Nasdaq standards and will receive standard non-employee director compensation.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Wendy L. Dixon

Director

BDTX · Black Diamond Therapeutics, Inc.

Effective: 2024-04-10
Filed: April 11, 2024, 7:59 PM ET

Wendy L. Dixon, Ph.D. resigned from the Board and all committees thereof, including her position as Chair of the Nominating and Corporate Governance Committee of the Board

Appointed

Prakash Raman

Director

BDTX · Black Diamond Therapeutics, Inc.

Effective: 2024-04-10
Filed: April 11, 2024, 7:59 PM ET

the Board appointed (i) Prakash Raman, Ph.D. to serve on the Board as a Class I director

Departed

Alexander Mayweg

Director

BDTX · Black Diamond Therapeutics, Inc.

Effective: 2024-04-10
Filed: April 11, 2024, 7:59 PM ET

Alexander Mayweg, Ph.D. resigned from the Board of Directors (the “Board”) of Black Diamond Therapeutics, Inc. (the “Company”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Wendy L. Dixon resigned as Director at Black Diamond Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

Wendy L. Dixon, Ph.D. resigned from the Board and all committees thereof, including her position as Chair of the Nominating and Corporate Governance Committee of the Board

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Prakash Raman was appointed as Director at Black Diamond Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board appointed (i) Prakash Raman, Ph.D. to serve on the Board as a Class I director

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Alexander Mayweg resigned as Director at Black Diamond Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

Alexander Mayweg, Ph.D. resigned from the Board of Directors (the “Board”) of Black Diamond Therapeutics, Inc. (the “Company”).

View on SEC.gov

Black Diamond Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-046096

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.